Silvia Aleman-Arteaga

Dr. Silvia Aleman-Arteaga

Oncohematology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
orcid
Junior Postdoctoral Researcher

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
GRGuillermo Rodríguez-Hernández
Guillermo Rodríguez-Hernández
ACAna Casado-García
Ana Casado-García
MIMarta Isidro-Hernández
Marta Isidro-Hernández
DPDaniel Picard
Daniel Picard
JRJavier Raboso-Gallego
Javier Raboso-Gallego
CVCarolina Vicente-Dueñas
Carolina Vicente-Dueñas
ETV6-RUNX1 is almost exclusively associated with childhood B-cell acute lymphoblastic leukemia (B-ALL), but the consequences of ETV6-RUNX1 expression on cell lineage decisions during B-cell leukemogenesis are completely unknown. Clinically silent ETV6-RUNX1 preleukemic clones are frequently found in neonatal cord blood, but few carriers develop B-ALL as a result of secondary genetic alterations. The understanding of the mechanisms underlying the first transforming steps could greatly advance the development of non-toxic prophylactic interventions. Using genetic lineage tracing, we examined the capacity of ETV6-RUNX1 to instruct a malignant phenotype in the hematopoietic lineage by cell-specific Cre-mediated activation of ETV6-RUNX1 from the endogenous Etv6 gene locus. Here we show that, while ETV6-RUNX1 has the propensity to trigger both T- and B-lymphoid malignancies, it is the second hit that determines tumor cell identity. To instigate leukemia, both oncogenic hits must place early in the development of hematopoietic/precursor cells, not in already committed B-cells. Depending on the nature of the second hit, the resulting B-ALLs presented distinct entities that were clearly separable based on their gene expression profiles. Our findings give a novel mechanistic insight into the early steps of ETV6-RUNX1+ B-ALL development and might have major implications for the potential development of ETV6-RUNX1+ B-ALL prevention strategies.

6 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
CKCamille Keenan
Camille Keenan
SASabrin Albeituni
Sabrin Albeituni
NONinad Oak
Ninad Oak
ASAlexa N Stroh
Alexa N Stroh
HTHeather S. Tillman
Heather S. Tillman
KNKim E. Nicols
Kim E. Nicols
Hemophagocytic lymphohistiocytosis (HLH) comprises a severe hyperinflammatory phenotype driven by the overproduction of cytokines, many of which signal via the JAK/STAT pathway. Indeed, the JAK1/2 inhibitor ruxolitinib has demonstrated efficacy in preclinical studies and early-phase clinical trials in HLH. Nevertheless, concerns remain for ruxolitinib-induced cytopenias, which are postulated to result from the blockade of JAK2-dependent hematopoietic growth factors. To explore the therapeutic effects of selective JAK inhibition in mouse models of HLH, we carried out studies incorporating the JAK1 inhibitor itacitinib, JAK2 inhibitor fedratinib, and JAK1/2 inhibitor ruxolitinib. All 3 drugs were well-tolerated and at the doses tested, they suppressed interferon-gamma (IFN-γ)–induced STAT1 phosphorylation in vitro and in vivo. Itacitinib, but not fedratinib, significantly improved survival and clinical scores in CpG–induced secondary HLH. Conversely, in primary HLH, in which perforin-deficient (Prf1−/−) mice are infected with lymphocytic choriomeningitis virus (LCMV), itacitinib, and fedratinib performed suboptimally. Ruxolitinib demonstrated excellent clinical efficacy in both HLH models. RNA-sequencing of splenocytes from LCMV-infected Prf1−/− mice revealed that itacitinib targeted inflammatory and metabolic pathway genes in CD8 T cells, whereas fedratinib targeted genes regulating cell proliferation and metabolism. In monocytes, neither drug conferred major transcriptional impacts. Consistent with its superior clinical effects, ruxolitinib exerted the greatest transcriptional changes in CD8 T cells and monocytes, targeting more genes across several biologic pathways, most notably JAK-dependent proinflammatory signaling. We conclude that JAK1 inhibition is sufficient to curtail CpG-induced disease, but combined inhibition of JAK1 and JAK2 is needed to best control LCMV-induced immunopathology.

24 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MIMarta Isidro-Hernández
Marta Isidro-Hernández
ACAna Casado-García
Ana Casado-García
NONinad Oak
Ninad Oak
Silvia Aleman-ArteagaSilvia Aleman-Arteaga
Silvia Aleman-Arteaga
BRBelén Ruiz-Corzo
Belén Ruiz-Corzo
ISIsidro Sanchez-Garcia
Isidro Sanchez-Garcia
The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignantPax5+/−B-cell precursors toward leukemia. Transcriptional profiling reveals thatMyd88is downregulated in immune-stressed pre-malignant B-cell precursors and in leukemic cells. Genetic reduction ofMyd88expression leads to a significant increase in leukemia incidence inPax5+/−Myd88+/−mice through an inflammation-dependent mechanism. Early induction of Myd88-independent Toll-like receptor 3 signaling results in a significant delay of leukemia development inPax5+/−mice. Altogether, these findings identify a role for innate immunity dysregulation in leukemia, with important implications for understanding and therapeutic targeting of the preleukemic state in children.

15 March 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
ACAna Casado-García
Ana Casado-García
MIMarta Isidro-Hernández
Marta Isidro-Hernández
NONinad Oak
Ninad Oak
AMAndrea Mayado
Andrea Mayado
CMChristine Mann-Ran
Christine Mann-Ran
ISIsidro Sanchez-Garcia
Isidro Sanchez-Garcia
Preventing development of childhood B-cell acute lymphoblastic leukemia (B-ALL), a disease with devastating effects, is a longstanding and unsolved challenge. Heterozygous germline alterations in the PAX5 gene can lead to B-ALL upon accumulation of secondary mutations affecting the JAK/STAT signaling pathway. Preclinical studies have shown that this malignant transformation occurs only under immune stress such as exposure to infectious pathogens. Here we show in Pax5+/− mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigates the risk of B-ALL following exposure to infection; 1 of 29 animals treated with ruxolitinib developed B-ALL versus 8 of 34 untreated mice. Ruxolitinib treatment preferentially targeted Pax5+/− versus wild-type B-cell progenitors and exerted unique effects on the Pax5+/− B-cell progenitor transcriptional program. These findings provide the first in vivo evidence for a potential strategy to prevent B-ALL development. Significance: JAK/STAT inhibition suppresses tumorigenesis in a B-ALL–susceptible mouse model, presenting a novel approach to prevent B-ALL onset.

Verified
Journal Article
Open access
PDF file
MIMarta Isidro-Hernández
Marta Isidro-Hernández
Silvia Aleman-ArteagaSilvia Aleman-Arteaga
Silvia Aleman-Arteaga
ACAna Casado-García
Ana Casado-García
BRBelén Ruiz-Corzo
Belén Ruiz-Corzo
SRSusana Riesco
Susana Riesco
CVCarolina Vicente-Dueñas
Carolina Vicente-Dueñas
Leukemia is the most usual childhood cancer, and B-cell acute lymphoblastic leukemia (B-ALL) is its most common presentation. It has been proposed that pediatric leukemogenesis occurs through a “multi-step” or “multi-hit” mechanism that includes both in utero and postnatal steps. Many childhood leukemia-initiating events, such as chromosomal translocations, originate in utero, and studies so far suggest that these “first-hits” occur at a far higher frequency than the incidence of childhood leukemia itself. The reason why only a small percentage of the children born with such preleukemic “hits” will develop full-blown leukemia is still a mystery. In order to better understand childhood leukemia, mouse modeling is essential, but only if the multistage process of leukemia can be recapitulated in the model. Therefore, mouse models naturally reproducing the “multi-step” process of childhood B-ALL will be essential to identify environmental or other factors that are directly linked to increased risk of disease.

7 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAna Casado-García
Ana Casado-García
GGGonzalo García-Aguilera
Gonzalo García-Aguilera
JPJulio Pozo
Julio Pozo
NONinad Oak
Ninad Oak
SBSusana Barrena
Susana Barrena
ISIsidro Sanchez-Garcia
Isidro Sanchez-Garcia
In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often by unknown mechanisms. Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis but in the absence of PD-1, tumor cells express NK cell inhibitory receptors highlighting the necessity for leukemic cells to evade the host's NK immune response in order to exit the bone marrow. PD-1 expression reduces natural anti-tumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefit by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.